News

Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ 26-02-2013
Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™. This study will be a Phase II... read more 

Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ 21-01-2013
Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product... read more 

About us

Kiadis Pharma in brief

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

With regard to Kiadis Pharma’s lead product ATIR™, and based upon a phase I/II dose escalation study providing early proof of concept of the safety and efficacy of ATIRTM, Kiadis Pharma started a larger phase II/III study in 2009 which was terminated early in 2012 due to major manufacturing issues. At the same time, Hospira, Inc., Kiadis Pharma’s partner for ATIR™ in Europe, terminated its agreement with Kiadis Pharma. The manufacturing issues encountered by Kiadis Pharma have been resolved and it is anticipated that a multi-center phase II exploratory study to evaluate the safety and efficacy of ATIRTM will commence enrolling patients early 2013.
 

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51